Handgrip Strength (HGS) With HGS Asymmetry Are Associated With All-cause Mortality and Hospital Readmissions
1 other identifier
observational
342
1 country
1
Brief Summary
Adding the handgrip strength (HGS) asymmetry to the existing measurements of low HGS may improve the assessment of muscle function.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 30, 2022
CompletedFirst Submitted
Initial submission to the registry
May 26, 2022
CompletedFirst Posted
Study publicly available on registry
May 31, 2022
CompletedMay 31, 2022
May 1, 2022
1.1 years
May 26, 2022
May 26, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
All-cause mortality
within 3 months after surgery, collected from telephone follow-up
about 3 months
Hospital readmissions
wihthin 3 months after surgery, collected from telephone follow-up
about 3 months
Secondary Outcomes (2)
Total complications
about 3 months
prolonged length of stay
about 3 months
Study Arms (4)
Full robust
no low HGS without HGS asymmetry
low HGS alone
low HGS without HGS asymmetry
HGS asymmetry alone
no low HGS with HGS asymmetry
low HGS with HGS asymmetry
non
Interventions
This is an observational study with no intervention.
Eligibility Criteria
elderly patients with gastric cancer
You may qualify if:
- with gastric cancer
- aged ≥60 years
- were scheduled to undergo radical surgery for the first time
You may not qualify if:
- received preoperative radiotherapy or chemotherapy
- combined with other types of malignant tumors
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nanjing medical university
Nanjing, China
Biospecimen
Not
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
xueyi miao
Nanjing Medical University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 26, 2022
First Posted
May 31, 2022
Study Start
March 1, 2021
Primary Completion
March 30, 2022
Study Completion
March 30, 2022
Last Updated
May 31, 2022
Record last verified: 2022-05
Data Sharing
- IPD Sharing
- Will not share